Antisense-MDM2 Sensitizes LNCaP Prostate Cancer Cells to Androgen Deprivation, Radiation, and the Combination In Vivo
- 15 July 2007
- journal article
- Published by Elsevier BV in International Journal of Radiation Oncology*Biology*Physics
- Vol. 68 (4), 1151-1160
- https://doi.org/10.1016/j.ijrobp.2007.03.047
Abstract
No abstract availableKeywords
This publication has 53 references indexed in Scilit:
- Bcl-2 and bax expression and prostate cancer outcome in men treated with radiotherapy in Radiation Therapy Oncology Group protocol 86-10International Journal of Radiation Oncology*Biology*Physics, 2006
- Stabilization of E2F1 protein by MDM2 through the E2F1 ubiquitination pathwayOncogene, 2005
- MDM2 as a predictor of prostate carcinoma outcomeCancer, 2005
- MDM2 Is a Negative Regulator of p21 , Independent of p53Published by Elsevier BV ,2004
- Antisense MDM2 oligonucleotides restore the apoptotic response of prostate cancer cells to androgen deprivationThe Prostate, 2004
- Chemosensitization and Radiosensitization of Human Cancer by Antisense Anti‐MDM2 OligonucleotidesAnnals of the New York Academy of Sciences, 2003
- Regulation of p53 stability by Mdm2Nature, 1997
- Mdm2 promotes the rapid degradation of p53Nature, 1997
- Defining a Functional Androgen Responsive Element in the 5′ Far Upstream Flanking Region of the Prostate-Specific Antigen GeneBiochemical and Biophysical Research Communications, 1997
- Suramin-Induced Decrease in Prostate-Specific Antigen Expression With No Effect on Tumor Growth in the LNCaP Model of Human Prostate CancerJNCI Journal of the National Cancer Institute, 1996